Antiapoptotic Activity of Alzheimer Abeta

阿尔茨海默病 Abeta 的抗凋亡活性

基本信息

  • 批准号:
    6321451
  • 负责人:
  • 金额:
    $ 22.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-06-01 至 2004-05-31
  • 项目状态:
    已结题

项目摘要

Alzheimer's disease (AD) is a debilitating neurodegenerative disease that is characterized by neuronal cell loss and the deposition of protein aggregates. These neuropathological parameters are correlated with the presence of numerous markers of oxidative stress in the cell bodies of neurons suggesting the involvement of oxidative mechanisms in neuronal cell loss and/or protein deposition. Although the sources of the reactive oxygen species (ROS) leading to this oxidative stress have not been clarified, the brain responds to this chronic oxidative challenge by upregulating antioxidant defense systems (eg. increasing SOD1 and glutathione peroxidase expression). We now have three lines of evidence indicating that the increased generation of Abeta in AD also may be a compensatory response to oxidative stress that prevents neuronal apoptosis. Firstly, we have determined from in vitro studies that Abeta has significant antioxidant (superoxide dismutase) activity, secondly, that nanomolar concentrations of Abeta block apoptosis of neurons following trophic factor withdrawal, and thirdly that the Abeta amyloid burden of the AD-affected brain is significantly negatively correlated with oxidative stress markers. In support of these findings, we find fewer oxidative modifications in amyloid deposits and neurofibrillary tangles compared with the cell bodies of the neurons of AD-affected brains. Together, these compelling data provide a plausible physiological explanation for the increased generation of Abeta in AD and following head trauma. We hypothesize that as the disease progresses, the chronic overproduction of hydrogen peroxide by neuronal cells, microglia and Abeta amyloid deposits may overwhelm the antioxidant defense systems of the aging brain with the end result that ROS promote the apoptotic demise. Thus, the novel aspect of our hypothesis is the recognition that Abeta generation may be a form of pleiotrophic antagonism, whereby Abeta may be physiologically purposive under "normal" conditions (i.e. moderately increased concentrations of superoxide and/or high reducing equivalents), but may promote neuronal cell death under abnormal conditions (i.e. high concentrations of superoxide and Abeta that lead to excess hydrogen peroxide/low reducing equivalents). The proposed studies will therefore examine the generation of Abeta as a compensatory mechanism to oxidative stress that is both antioxidant and anti-apoptotic in nature while testing whether overwhelming oxidative challenges promote apoptosis. We also will test whether oxidative stress induces neurons to re-enter the cell cycle as a mechanism leading to cell death.
阿尔茨海默病(AD)是一种以神经元细胞损失和蛋白质聚集体沉积为特征的使人衰弱的神经退行性疾病。这些神经病理学参数与神经元细胞体中氧化应激的许多标志物的存在相关,表明氧化机制参与神经元细胞损失和/或蛋白质沉积。虽然导致这种氧化应激的活性氧(ROS)的来源尚未阐明,但大脑通过上调抗氧化防御系统(例如,抗氧化防御系统)来应对这种慢性氧化挑战。增加SOD 1和谷胱甘肽过氧化物酶表达)。我们现在有三条证据表明AD中Abeta的产生增加也可能是对氧化应激的代偿反应,从而防止神经元凋亡。首先,我们已经确定,从体外研究中,Abeta具有显着的抗氧化剂(超氧化物歧化酶)活性,其次,纳摩尔浓度的Abeta阻断神经元凋亡后的营养因子撤退,第三,AD影响的大脑的Abeta淀粉样蛋白负荷显着负相关的氧化应激标志物。为了支持这些发现,我们发现与AD影响的大脑神经元的细胞体相比,淀粉样蛋白沉积物和神经元缠结中的氧化修饰较少。总之,这些令人信服的数据为AD和头部创伤后Abeta的产生增加提供了合理的生理学解释。我们假设,随着疾病的进展,神经元细胞,小胶质细胞和Abeta淀粉样蛋白沉积物的过氧化氢的慢性过度产生可能会压倒衰老大脑的抗氧化防御系统,最终结果是ROS促进凋亡死亡。因此,我们的假说的新颖之处在于认识到Abeta的产生可能是一种多效性拮抗作用的形式,因此Abeta在“正常”条件下可能具有生理目的性(即适度增加的超氧化物和/或高还原当量的浓度),但在异常条件下可能促进神经元细胞死亡(即高浓度的超氧化物和Abeta,导致过量的过氧化氢/低还原当量)。因此,拟议的研究将检查Abeta的产生作为氧化应激的补偿机制,其本质上既是抗氧化剂又是抗凋亡的,同时测试压倒性的氧化挑战是否会促进凋亡。我们还将测试氧化应激是否诱导神经元重新进入细胞周期作为导致细胞死亡的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Craig S Atwood其他文献

Craig S Atwood的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Craig S Atwood', 18)}}的其他基金

The LUCINDA Trial
露辛达审判
  • 批准号:
    10412901
  • 财政年份:
    2018
  • 资助金额:
    $ 22.95万
  • 项目类别:
The LUCINDA Trial
露辛达审判
  • 批准号:
    9988337
  • 财政年份:
    2018
  • 资助金额:
    $ 22.95万
  • 项目类别:
The LUCINDA Trial
露辛达审判
  • 批准号:
    9933921
  • 财政年份:
    2018
  • 资助金额:
    $ 22.95万
  • 项目类别:
The LUCINDA Trial
露辛达审判
  • 批准号:
    9597000
  • 财政年份:
    2018
  • 资助金额:
    $ 22.95万
  • 项目类别:
What Genes Experience:Environmental Moderators of Genetic Risk in MIDUS
基因经历了什么:MIDUS 遗传风险的环境调节因素
  • 批准号:
    8719412
  • 财政年份:
    2013
  • 资助金额:
    $ 22.95万
  • 项目类别:
Epistasis in Steroidogenic Genes in the Prediction of Alzheimer's Disease
类固醇生成基因的上位性在阿尔茨海默病的预测中的作用
  • 批准号:
    8440478
  • 财政年份:
    2012
  • 资助金额:
    $ 22.95万
  • 项目类别:
Epistasis in Steroidogenic Genes in the Prediction of Alzheimer's Disease
类固醇生成基因的上位性在阿尔茨海默病的预测中的作用
  • 批准号:
    8598792
  • 财政年份:
    2012
  • 资助金额:
    $ 22.95万
  • 项目类别:
Antiapoptotic Activity of Alzheimer Abeta
阿尔茨海默病 Abeta 的抗凋亡活性
  • 批准号:
    6631585
  • 财政年份:
    2001
  • 资助金额:
    $ 22.95万
  • 项目类别:
Antiapoptotic Activity of Alzheimer Abeta
阿尔茨海默病 Abeta 的抗凋亡活性
  • 批准号:
    6509977
  • 财政年份:
    2001
  • 资助金额:
    $ 22.95万
  • 项目类别:
REDOX METAL IONS AND NEURONAL PROTEIN DEPOSITION
氧化还原金属离子和神经元蛋白沉积
  • 批准号:
    2859119
  • 财政年份:
    1999
  • 资助金额:
    $ 22.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了